| CAS NO: | 496955-42-1 |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| Cas No. | 496955-42-1 |
| Canonical SMILES | CCCCC1=NC(N)=C2C(N(C)C(N3N=CC=N3)=N2)=N1 |
| 分子式 | C12H16N8 |
| 分子量 | 272.3 |
| 溶解度 | DMF: 5mg/mL,DMSO: 5mg/mL,DMSO:PBS (pH 7.2) (1:9): 0.1mg/mL |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | ST1535 is an adenosine A2Areceptor antagonist.1It is selective for adenosine A2Aover A1receptors (Kis = 2.3 and 107 nM, respectively, in radioligand binding assays). ST1535 inhibits agonist-induced production of cAMP in CHO cells expressing adenosine A2Areceptors (IC50= 353 nM).In vivo,ST1535 (10 and 20 mg/kg) reduces haloperidol-induced catalepsy in mice. It reduces the number of jaw tremors in a rat model of Parkinsonian jaw tremors induced by tacrine .2ST1535 (20 and 40 mg/kg) increases locomotor activity and reverses motor disabilities in a marmoset model of MPTP-induced Parkinson's disease.3 1.Stasi, M.A., Borsini, F., Varani, K., et al.ST 1535: a preferential A2A adenosine receptor antagonistInt. J. Neuropsychopharmacol.9(5)575-584(2006) 2.Tronci, E., Simola, N., Borsini, F., et al.Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in ratsEur. J. Pharmacol.566(1-3)94-102(2007) 3.Rose, S., Jackson, M.J., Smith, L.A., et al.The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosetsEur. J. Pharmacol.546(1-3)82-87(2006) |
m.cnreagent.com